New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
Guardant Health (Nasdaq: GH) released its second annual 'Closing the Gap: CRC Screening Insights' survey, revealing significant barriers to colorectal cancer (CRC) screening. The Harris Poll survey of 1,000 adults aged 45-84 and 350 physicians showed that patient fear and anxiety are increasing barriers to screening, with 29% of patients reporting these concerns, up from 22% in 2024.
Key findings include that 93% of primary care providers believe patients are less likely to avoid screening if offered an FDA-approved blood test option. The survey highlighted that over 50 million Americans are not up-to-date with CRC screening, with People of Color showing lower screening rates (63%) compared to white people (72%).
Guardant Health's Shield blood test, recently FDA-approved as a primary CRC screening option, offers a more convenient alternative to traditional methods. The test requires no preparation or invasive procedures and can be completed during routine healthcare visits. 92% of Americans indicated they would be more satisfied with their wellness visit if offered this blood test option and more likely to get a colonoscopy following a positive blood test result.
Guardant Health (Nasdaq: GH) ha pubblicato il suo secondo sondaggio annuale 'Closing the Gap: CRC Screening Insights', rivelando significativi ostacoli alla screening del cancro colorettale (CRC). Il sondaggio condotto da Harris Poll su 1.000 adulti di età compresa tra 45 e 84 anni e 350 medici ha mostrato che la paura e l'ansia dei pazienti stanno aumentando come barriere alla screening, con il 29% dei pazienti che riporta queste preoccupazioni, in aumento rispetto al 22% del 2024.
I risultati chiave includono che il 93% dei medici di medicina generale crede che i pazienti siano meno propensi a evitare la screening se viene offerta un'opzione di test del sangue approvata dalla FDA. Il sondaggio ha evidenziato che oltre 50 milioni di americani non sono aggiornati con la screening CRC, con le persone di colore che mostrano tassi di screening più bassi (63%) rispetto ai bianchi (72%).
Il test del sangue Shield di Guardant Health, recentemente approvato dalla FDA come opzione principale per la screening CRC, offre un'alternativa più conveniente ai metodi tradizionali. Il test non richiede preparazione o procedure invasive e può essere completato durante le visite sanitarie di routine. Il 92% degli americani ha indicato che sarebbe più soddisfatto della propria visita di benessere se venisse offerta questa opzione di test del sangue e sarebbe più propenso a sottoporsi a una colonscopia dopo un risultato positivo del test del sangue.
Guardant Health (Nasdaq: GH) lanzó su segunda encuesta anual 'Closing the Gap: CRC Screening Insights', revelando barreras significativas para la detección del cáncer colorrectal (CRC). La encuesta de Harris Poll de 1,000 adultos de entre 45 y 84 años y 350 médicos mostró que el miedo y la ansiedad de los pacientes están aumentando como barreras para la detección, con el 29% de los pacientes informando estas preocupaciones, un aumento del 22% en 2024.
Los hallazgos clave incluyen que el 93% de los proveedores de atención primaria creen que los pacientes son menos propensos a evitar la detección si se les ofrece una opción de prueba de sangre aprobada por la FDA. La encuesta destacó que más de 50 millones de estadounidenses no están al día con la detección de CRC, con las personas de color mostrando tasas de detección más bajas (63%) en comparación con los blancos (72%).
El test de sangre Shield de Guardant Health, recientemente aprobado por la FDA como una opción principal para la detección de CRC, ofrece una alternativa más conveniente a los métodos tradicionales. La prueba no requiere preparación ni procedimientos invasivos y se puede completar durante las visitas de atención médica de rutina. El 92% de los estadounidenses indicó que estaría más satisfecho con su visita de bienestar si se les ofreciera esta opción de prueba de sangre y sería más propenso a hacerse una colonoscopia tras un resultado positivo de la prueba de sangre.
Guardant Health (Nasdaq: GH)는 두 번째 연례 조사 'Closing the Gap: CRC Screening Insights'를 발표하며 대장암(CRC) 검진에 대한 중요한 장벽을 드러냈습니다. 45세에서 84세 사이의 성인 1,000명과 의사 350명을 대상으로 한 Harris Poll 조사에 따르면, 환자의 두려움과 불안이 검진에 대한 장벽으로 증가하고 있으며, 29%의 환자가 이러한 우려를 보고했으며, 이는 2024년의 22%에서 증가한 수치입니다.
주요 발견 사항으로는 93%의 1차 진료 제공자가 FDA 승인 혈액 검사 옵션이 제공되면 환자들이 검진을 피할 가능성이 낮아진다고 믿고 있다는 점입니다. 조사에 따르면 5천만 명 이상의 미국인이 CRC 검진을 받지 않고 있으며, 유색인종의 검진 비율은 백인(72%)에 비해 낮은 63%로 나타났습니다.
Guardant Health의 Shield 혈액 검사는 최근 FDA에서 주요 CRC 검진 옵션으로 승인되어 전통적인 방법에 대한 더 편리한 대안을 제공합니다. 이 검사는 준비나 침습적인 절차가 필요하지 않으며, 정기 건강 검진 중에 완료할 수 있습니다. 92%의 미국인이 이 혈액 검사 옵션이 제공된다면 자신의 건강 검진에 더 만족할 것이라고 응답했으며, 긍정적인 혈액 검사 결과 후 대장내시경 검사를 받을 가능성이 더 높아질 것이라고 밝혔습니다.
Guardant Health (Nasdaq: GH) a publié sa deuxième enquête annuelle 'Closing the Gap: CRC Screening Insights', révélant des obstacles significatifs à la détection du cancer colorectal (CRC). L'enquête de Harris Poll auprès de 1.000 adultes âgés de 45 à 84 ans et de 350 médecins a montré que la peur et l'anxiété des patients constituent des obstacles croissants à la détection, 29 % des patients rapportant ces préoccupations, en hausse par rapport à 22 % en 2024.
Les résultats clés incluent que 93 % des médecins de soins primaires estiment que les patients sont moins enclins à éviter le dépistage s'ils se voient proposer une option de test sanguin approuvée par la FDA. L'enquête a souligné que plus de 50 millions d'Américains ne sont pas à jour avec le dépistage du CRC, les personnes de couleur affichant des taux de dépistage plus bas (63 %) par rapport aux personnes blanches (72 %).
Le test sanguin Shield de Guardant Health, récemment approuvé par la FDA comme option principale pour le dépistage du CRC, offre une alternative plus pratique aux méthodes traditionnelles. Le test ne nécessite aucune préparation ni procédure invasive et peut être réalisé lors de visites de soins de santé de routine. 92 % des Américains ont indiqué qu'ils seraient plus satisfaits de leur visite de bien-être si cette option de test sanguin leur était proposée et qu'ils seraient plus susceptibles de subir une coloscopie après un résultat positif du test sanguin.
Guardant Health (Nasdaq: GH) hat seine zweite jährliche Umfrage 'Closing the Gap: CRC Screening Insights' veröffentlicht, die erhebliche Barrieren bei der Früherkennung von Darmkrebs (CRC) aufzeigt. Die Harris Poll-Umfrage unter 1.000 Erwachsenen im Alter von 45 bis 84 Jahren und 350 Ärzten ergab, dass die Angst und die Sorgen der Patienten zunehmende Barrieren für die Screening darstellen, wobei 29% der Patienten diese Bedenken äußern, ein Anstieg von 22% im Jahr 2024.
Wichtige Ergebnisse umfassen, dass 93% der Hausärzte glauben, dass Patienten weniger wahrscheinlich auf das Screening verzichten, wenn ihnen eine von der FDA genehmigte Bluttest-Option angeboten wird. Die Umfrage hob hervor, dass über 50 Millionen Amerikaner nicht auf dem neuesten Stand mit der CRC-Screening sind, wobei People of Color niedrigere Screening-Raten (63%) im Vergleich zu weißen Menschen (72%) aufweisen.
Der Shield-Bluttest von Guardant Health, der kürzlich von der FDA als primäre CRC-Screening-Option genehmigt wurde, bietet eine bequemere Alternative zu herkömmlichen Methoden. Der Test erfordert keine Vorbereitung oder invasive Verfahren und kann während routinemäßiger Gesundheitsbesuche durchgeführt werden. 92% der Amerikaner gaben an, dass sie mit ihrem Gesundheitsbesuch zufriedener wären, wenn ihnen diese Bluttest-Option angeboten würde, und sie eher bereit wären, sich nach einem positiven Bluttestergebnis einer Koloskopie zu unterziehen.
- None.
- None.
-
93% of primary care providers believe patients are less likely to avoid screening if presented with an FDA-approved blood test option - March is Colorectal Cancer Awareness Month
- Shield is first blood test approved by FDA as a primary screening option for CRC
Conducted by The Harris Poll, Guardant’s annual survey of American patients and physicians is released during Colorectal Cancer Awareness Month to assess Americans’ understanding of the importance of CRC screening and the perceived barriers that may cause them to delay or avoid completing recommended screening. The survey polled 1,000 American adults (referred to as patients) ages 45-84, along with 350 physicians (250 primary care providers and 100 gastroenterologists).*
More than one out of three eligible Americans – over 50 million people – are not up to date with CRC screening, often due to the perception that traditional methods - colonoscopy and stool tests - are unpleasant or inconvenient.1 In fact, this year’s survey noted that fear and anxiety about the process is growing, providing one possible reason for the persistent CRC screening gap:
-
Close to a third of patients report feeling fear or anxiety about the CRC screening process — an increase compared to February 2024 (
29% vs22% ). -
Similarly,
82% of gastroenterologists believe fear or anxiety is a barrier to their patients completing CRC screening – also up from 2024’s survey (82% vs.67% ). -
Having a quicker, easier, more pleasant screening option (vs. traditional methods) is a top motivating factor for staying up to date on CRC screenings. In fact, compared to a year ago, more Americans – now 1 in 4 – say that traditional screening tests do not make it easy to screen for CRC (
24% vs18% ). -
93% of primary care providers and86% of Americans believe patients are less likely to avoid or delay CRC screenings if they are presented with an FDA-approved blood test option.
“This year’s survey conducted by The Harris Poll confirms that one reason millions of Americans may avoid recommended CRC screening is fear and anxiety about the process. But there is also promising news: the vast majority of physicians and patients believe avoiding screening is less likely if patients have an FDA-approved blood test option,” said Craig Eagle, M.D., Guardant Health chief medical officer. “The Shield™ blood test can be completed at any routine healthcare visit and requires no preparation, no invasive procedure, and no handling of your own stool. Offering patients the more pleasant, convenient option of a blood test has the potential to improve CRC screening rates and ultimately save more lives.”
CRC is highly treatable when caught in early stages, yet it is the second-leading cause of cancer-related death in the
Additional ‘Closing the Gap: CRC Screening Insights’ 2025 Survey Findings
-
92% of Americans say they would be more satisfied with their wellness visit if their provider offered an FDA-approved blood test as an option for a CRC screening. -
92% of Americans also say they would be more likely to get a colonoscopy if they had a positive result on a blood screening first. -
Despite being more concerned about CRC and feeling at higher risk, People of Color (POC) are less likely to have been screened (
63% vs.72% of white people).-
According to the American Cancer Society, Black people are about
20% more likely to get CRC and about40% more likely to die from it than most other racial and ethnic groups in theU.S. 5
-
According to the American Cancer Society, Black people are about
Shield is the first blood test to be approved by the
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
About The Harris Poll
The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. One of the longest-running surveys in the
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
* The Harris Poll conducted the survey on behalf of Guardant Health in December 2024. It included over 1,000
References
- Rich T, Raymond V, Lang K. Where are we today? Efforts to understand strategies and barriers to physician issuance of a recommendation for colorectal cancer screening: a systematic review. Gastroenterology. 2020;158(6 suppl 1):S-918. doi:10.1016/S0016-5085(20)32981-4.
- American Cancer Society. Cancer Facts & Figures 2024. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2024/2024-cancer-facts-and-figures-acs.pdf. Accessed February 19, 2025.
- American Cancer Society. Guideline for Colorectal Cancer Screening. https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html Accessed February 19, 2025.
- Doubeni, C, et al. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association with Risk of Death. Gastroenterology. 2019 Jan; 156(1): 63–74.e6.
- American Cancer Society. Colorectal Cancer Rates Higher in African Americans, Rising in Younger People. https://www.cancer.org/cancer/latest-news/colorectal-cancer-rates-higher-in-african-americans-rising-in-younger-people.html Accessed February 19, 2025.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227632736/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What are the key findings of Guardant Health's (GH) 2025 CRC screening survey?
How does Guardant Health's Shield blood test differ from traditional CRC screening methods?
What are the racial disparities in CRC screening rates according to GH's survey?
How many Americans are currently not up-to-date with CRC screening according to the survey?
What percentage of patients would get a colonoscopy after a positive Shield blood test?
